How does treatment coverage and proportion never treated influence the success of Schistosoma mansoni elimination as a public health problem by 2030?
Klodeta Kura, Nyamai Mutono, Maria-Gloria Basáñez, View ORCID ProfileLuc E. Coffeng, S.M. Thumbi, Roy M. Anderson
doi: https://doi.org/10.1101/2023.10.20.23297322
Klodeta Kura
1London Centre for Neglected Tropical Disease Research, London, UK
2Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, St Mary’s Campus, Imperial College London, UK
3MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK
Nyamai Mutono
4Centre for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya
5Paul G Allen School for Global Health, Washington State University, Pullman, USA
Maria-Gloria Basáñez
1London Centre for Neglected Tropical Disease Research, London, UK
2Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, St Mary’s Campus, Imperial College London, UK
3MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK
Luc E. Coffeng
6Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
S.M. Thumbi
4Centre for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya
5Paul G Allen School for Global Health, Washington State University, Pullman, USA
7Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh, UK
Roy M. Anderson
1London Centre for Neglected Tropical Disease Research, London, UK
2Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, St Mary’s Campus, Imperial College London, UK
3MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, UK
Data Availability
All data produced in the present work are contained in the manuscript
Posted October 21, 2023.
How does treatment coverage and proportion never treated influence the success of Schistosoma mansoni elimination as a public health problem by 2030?
Klodeta Kura, Nyamai Mutono, Maria-Gloria Basáñez, Luc E. Coffeng, S.M. Thumbi, Roy M. Anderson
medRxiv 2023.10.20.23297322; doi: https://doi.org/10.1101/2023.10.20.23297322
How does treatment coverage and proportion never treated influence the success of Schistosoma mansoni elimination as a public health problem by 2030?
Klodeta Kura, Nyamai Mutono, Maria-Gloria Basáñez, Luc E. Coffeng, S.M. Thumbi, Roy M. Anderson
medRxiv 2023.10.20.23297322; doi: https://doi.org/10.1101/2023.10.20.23297322
Subject Area
Subject Areas
- Addiction Medicine (395)
- Allergy and Immunology (708)
- Anesthesia (199)
- Cardiovascular Medicine (2908)
- Dermatology (249)
- Emergency Medicine (436)
- Epidemiology (12679)
- Forensic Medicine (10)
- Gastroenterology (824)
- Genetic and Genomic Medicine (4534)
- Geriatric Medicine (412)
- Health Economics (723)
- Health Informatics (2897)
- Health Policy (1066)
- Hematology (383)
- HIV/AIDS (918)
- Medical Education (422)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4302)
- Nursing (233)
- Nutrition (631)
- Oncology (2250)
- Ophthalmology (640)
- Orthopedics (258)
- Otolaryngology (324)
- Pain Medicine (276)
- Palliative Medicine (83)
- Pathology (493)
- Pediatrics (1192)
- Primary Care Research (491)
- Public and Global Health (6885)
- Radiology and Imaging (1516)
- Respiratory Medicine (912)
- Rheumatology (433)
- Sports Medicine (381)
- Surgery (482)
- Toxicology (60)
- Transplantation (208)
- Urology (178)